Table 2.
Correlation between CXCL expression and tumor stage in DLBCL (TCGA).
| Clinical stage, n (%) | Stage I | Stage II | Stage III | Stage IV | p | |
|---|---|---|---|---|---|---|
| Characteristic | ||||||
| CXCL1 | High expression | 2 (4.8%) | 9 (21.4%) | 2 (4.8%) | 7 (16.7%) | 0.544 |
| Low expression | 6(14.3%) | 8 (19%) | 3 (7.1%) | 5 (11.9%) | ||
| CXCL2 | High expression | 0 (0%) | 10(23.8%) | 3 (7.1%) | 7 (16.7%) | 0.019 |
| Low expression | 8 (19%) | 7 (16.7%) | 2 (4.8%) | 5 (11.9%) | ||
| CXCL3 | High expression | 1 (2.4%) | 9 (21.4%) | 4 (9.5%) | 7 (16.7%) | 0.088 |
| Low expression | 7(16.7%) | 8 (19%) | 1 (2.4%) | 5 (11.9%) | ||
| CXCL4 | High expression | 3 (7.1%) | 8 (19%) | 3 (7.1%) | 6 (14.3%) | 0.917 |
| Low expression | 5(11.9%) | 9 (21.4%) | 2 (4.8%) | 6 (14.3%) | ||
| CXCL5 | High expression | 2 (4.8%) | 9 (21.4%) | 3 (7.1%) | 6 (14.3%) | 0.580 |
| Low expression | 6 (14.3%) | 8 (19%) | 2 (4.8%) | 6 (14.3%) | ||
| CXCL6 | High expression | 3 (7.1%) | 9 (21.4%) | 2 (4.8%) | 6 (14.3%) | 0.917 |
| Low expression | 5 (11.9%) | 8 (19%) | 3 (7.1%) | 6 (14.3%) | ||
| CXCL7 | High expression | 5 (11.9%) | 9 (21.4%) | 2 (4.8%) | 5 (11.9%) | 0.845 |
| Low expression | 3 (7.1%) | 8 (19%) | 3 (7.1%) | 7 (16.7%) | ||
| CXCL8 | High expression | 4 (9.5%) | 8 (19%) | 4 (9.5%) | 4 (9.5%) | 0.387 |
| Low expression | 4 (9.5%) | 9 (21.4%) | 1 (2.4%) | 8 (19%) | ||
| CXCL9 | High expression | 2 (4.8%) | 8 (19%) | 3 (7.1%) | 7 (16.7%) | 0.554 |
| Low expression | 6 (14.3%) | 9 (21.4%) | 2 (4.8%) | 5 (11.9%) | ||
| CXCL10 | High expression | 1 (2.4%) | 7 (16.7%) | 5 (11.9%) | 7 (16.7%) | 0.015 |
| Low expression | 7 (16.7%) | 10(23.8%) | 0 (0%) | 5 (11.9%) | ||
| CXCL11 | High expression | 1 (2.4%) | 8 (19%) | 5 (11.9%) | 6 (14.3%) | 0.021 |
| Low expression | 7 (16.7%) | 9 (21.4%) | 0 (0%) | 6 (14.3%) | ||
| CXCL12 | High expression | 4 (9.5%) | 6 (14.3%) | 3 (7.1%) | 6 (14.3%) | 0.742 |
| Low expression | 4 (9.5%) | 11 (26.2%) | 2 (4.8%) | 6 (14.3%) | ||
| CXCL13 | High expression | 5 (11.9%) | 6 (14.3%) | 3 (7.1%) | 4 (9.5%) | 0.485 |
| Low expression | 3 (7.1%) | 11 (26.2%) | 2 (4.8%) | 8 (19%) | ||
| CXCL14 | High expression | 4 (9.5%) | 6 (14.3%) | 4 (9.5%) | 6 (14.3%) | 0.379 |
| Low expression | 4 (9.5%) | 11 (26.2%) | 1 (2.4%) | 6 (14.3%) | ||
| CXCL16 | High expression | 2 (4.8%) | 10 (23.8%) | 2 (4.8%) | 7 (16.7%) | 0.434 |
| Low expression | 6 (14.3%) | 7 (16.7%) | 3 (7.1%) | 5 (11.9%) | ||
| CXCL17 | High expression | 4 (9.5%) | 9 (21.4%) | 3 (7.1%) | 4 (9.5%) | 0.690 |
| Low expression | 4 (9.5%) | 8 (19%) | 2 (4.8%) | 8 (19%) | ||
Significant values are in bold.